AbbVie Inc.

▲ Bull Case

• ◆Skyrizi captures Stelara's IBD patient base at 50%+ switching rate, reaching $28–32B peak revenue (vs. $28B base case), with combined immunology franchise peaking at $40–43B—exceeding any prior AbbVie or peer franchise peak
• ◆Cerevel emraclidine Phase 3 success (~2027) adds a novel schizophrenia mechanism generating $3–5B peak revenue by FY2032, validating neuroscience platform as next major growth vector and adding $25–40/share option value
• ◆Rinvoq IRA price impact is muted—Medicare represents only ~20% of patient base and CMS negotiates modest 15% price reduction rather than 25–30% bear scenario, allowing Rinvoq to sustain $12–13B through FY2030 combined with international ramp

▼ Bear Case

• ◆Rinvoq IRA negotiation arrives in 2028 CMS cohort with Medicare covering 30% of patient base; aggressive 25% price reduction reduces Rinvoq net revenues by $2.5–3B annually from FY2029 forward, compressing FCF to $19B or below
• ◆Dupixent and Omvoh capture 35%+ of Skyrizi's addressable IBD market via superior convenience despite IV administration, limiting Skyrizi peak to $24–25B rather than $28B+, materially missing growth assumptions
• ◆Cerevel emraclidine fails Phase 3 (~2027), triggering $3–4B goodwill impairment and invalidating neuroscience expansion thesis; requires fresh M&A adding $5–10B incremental debt while leverage target (2.5x) remains unmet

“The core debate centers on whether the $213 stock is pricing in a third consecutive successful pipeline replacement cycle or signals the last one. Bulls argue AbbVie demonstrated institutional capability to execute post-cliff transitions (Humira→Skyrizi/Rinvoq succeeded) and Cerevel/ImmunoGen represent two more attempts, with $9B/year R&D sufficient to generate next franchise at 14x NTM EBITDA. Bears counter that Skyrizi/Rinvoq are >70% through patent windows (2032–2037 LOE), no confirmed $20B+ Phase 3 asset exists to replace them, and $67.5B debt constrains M&A optionality. Secondary debate: IRA timing for Rinvoq—bears model 2028 CMS eligibility (vs. consensus 2030+), which would accelerate FCF compression by 2–3 years.”

• ◆Stelara LOE patient-switch data (H2 2026)—determines whether Skyrizi peaks at $24B (bear) or $28B+ (base/bull)
• ◆Cerevel emraclidine Phase 3 readout (~2027)—binary event worth $3–5B peak revenue ($25–40/share option value)
• ◆Rinvoq CMS negotiation cohort selection (2026–2027)—defines IRA price-cut timing (2028 vs. 2030+), $15–20/share valuation swing
• ◆Q2 2026 earnings (late July)—confirms beat-and-raise cadence; Skyrizi/Rinvoq growth >20–30% YoY validates base case
• ◆Elahere PICCOLO label expansion (FDA review 2026)—doubles addressable oncology market from $1.5B to $3B+
• ◆Annual dividend increase (Q4 2026)—signal of confidence; >6% raise affirms FCF coverage comfort
• ◆Tirvapadone Phase 3 (late 2026/early 2027)—derisks neuroscience platform beyond Cerevel binary

• ◆Rinvoq IRA price negotiation (2028 eligibility, 25–30% cut): $2–3B annual FCF reduction, moderate probability (40%)
• ◆Cerevel emraclidine Phase 3 failure (~2027): $3–4B impairment, invalidates neuroscience thesis, moderate probability (40–50%)
• ◆Skyrizi competitive erosion (Dupixent/Omvoh gain 35%+ IBD share): $2–4B peak revenue miss, moderate probability (30%)
• ◆Post-2032 patent cliff without replacement: no confirmed $20B+ Phase 3 asset; creates multiple compression 4–5 years pre-LOE, moderate-high probability (25–35%)
• ◆Leverage constraint on pipeline M&A: $67.5B debt limits acquisition capacity; organic R&D insufficient for franchise replacement, low-moderate probability (20%)
• ◆Aesthetics secular decline (GLP-1 weight loss reduces facial filler demand): $0.5–1B revenue headwind, moderate probability (30%)
• ◆CEO transition execution risk (Michael era vs. Gonzalez legacy): Robert Michael unproven in strategic decisions, low probability (15%)